# Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

> **NCT06008925** · PHASE1,PHASE2 · RECRUITING · sponsor: **CNBG-Virogin Biotech (Shanghai) Ltd.** · enrollment: 43 (estimated)

## Conditions studied

- Metastatic Gastric Cancer

## Interventions

- **DRUG:** Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- **DRUG:** Nivolumab Injection

## Key facts

- **NCT ID:** NCT06008925
- **Lead sponsor:** CNBG-Virogin Biotech (Shanghai) Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-17
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008925, "Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06008925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*